approval, and uncertainty about the requirement for conducting pediatric studies makes it difficult to plan and conduct the necessary studies.
In the early 1990s, the IOM focused concern on the lack of drug testing in children. In response to the IOM report, Congress and the FDA created legislation and policies to encourage greater incentives for the pharmaceutical industry to complete studies in children by providing an additional 6 months of exclusivity in the 1997 FDA Modernization Act. 4 Reauthorization of BPCA in 2002 created the Office of Pediatric Therapeutics within the FDA and created a Foundation at the National Institutes of Health to study ''off-patent'' drugs. PREA, first enacted in 2003, gives the FDA the authority to require drug manufacturers to complete studies in children for the same adult indications when the drugs are expected to be used in a substantial number of children. BPCA and PREA were both reauthorized by Congress in 2007.
Oncology drugs present a unique problem in children because children often have different cancers than those found in adults. 2 PREA currently requires that drugs be studied in children only for the same disease for which they are approved in adults. Drug companies cannot be required to study oncology drugs in children for different indications. A proposed solution would be to require that when a new cancer drug is approved that targets a specific disease pathway or gene mutation in an adult tumor, that drug would be required to be studied in pediatric tumors that share the same pathway or gene mutation.
It is time to make BPCA and PREA legislation permanent to assure continued investment in the study of safe and effective use of new medicines in infants and children.
